Radosevich J A, Robinson P G, Rittmann-Grauer L S, Wilson B, Leung J P, Maminta M L, Warren W, Rosen S T, Gould V E
Department of Pathology, Northwestern University/Veterans Administration Lakeside Medical Center, Chicago, Ill.
Tumour Biol. 1989;10(5):252-7. doi: 10.1159/000217622.
In this study, 212 untreated primary pulmonary and pleural neoplasms were studied immunohistochemically with the monoclonal antibody HYB-612 which detects the multidrug resistance (MDR)-related P-glycoprotein (gp180). A tumor was considered positive for the expression of the MDR phenotype, even if a single rare positive cell was detected. Using this criterion, all of the various histologic subtypes were found to express MDR to varying degrees. The frequency of expression of this phenotype was found to be notably higher in non-small-cell carcinomas than in small-cell carcinomas. These findings are consistent with the known clinical responses of these neoplasms. The detection of gp180 in untreated lung neoplasms may be predictive of the responsiveness of neoplasms to chemotherapeutic agents. In addition, its presence or absence might be useful in determining the appropriate treatment protocol for given patients.
在本研究中，使用检测多药耐药（MDR）相关P-糖蛋白（gp180）的单克隆抗体HYB-612，对212例未经治疗的原发性肺和胸膜肿瘤进行了免疫组织化学研究。即使仅检测到单个罕见的阳性细胞，肿瘤也被认为MDR表型表达呈阳性。采用这一标准，发现所有不同的组织学亚型均有不同程度的MDR表达。发现该表型在非小细胞癌中的表达频率显著高于小细胞癌。这些发现与这些肿瘤已知的临床反应一致。在未经治疗的肺肿瘤中检测gp180可能预测肿瘤对化疗药物的反应性。此外，其存在与否可能有助于为特定患者确定合适的治疗方案。
